We are live on !
Find out more
Thomas Steyer Farallon Capital Management
AUM
$21.7B
Turnover
63.92%
1-Year Est. Return
79.24%
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
(+14%)
Cap. Flow
-$3.46B
Cap. Flow % of AUM
Cap. Flow %
-15.95%
Top 10 Holdings %
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105
Avg Time Held
Equity + Options
1.9
years
Top 10 Avg Time Held
Equity + Options
0.5
years
Top 20 Avg Time Held
Equity + Options
1
year
Avg Time Held Equity only
2
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Miscellaneous | 21.83% |
| 3 | Communication Services | 8.41% |
| 4 | Technology | 5.7% |
| 5 | Financials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Abivax
ABVX
$8.16B
| $16.3M | 0.08% |
122,000
+120,000
| +6,000% | +$13.6M |
2025 Q3
3 quarters
|
|
52
VNET Group
VNET
$1.18B
| $16M | 0.07% |
1,992,000
+1,368,653
| +220% | +$12.4M |
2022 Q3
15 quarters
|
|
53
NetEase
NTES
$78.7B
| $15.8M | 0.07% |
123,500
-167,719
| -58% | -$19.8M |
2026 Q1
1 quarter
|
|
54
Biogen
BIIB
$35.6B
| $15.3M | 0.07% |
+71,000
| New | +$13.6M |
2026 Q2
0 quarters
|
|
55
Taysha Gene Therapies
TSHA
$1.34B
| $15.3M | 0.07% |
+2,250,000
| New | +$13.3M |
2026 Q2
0 quarters
|
|
56
Mobia Medical
MOBI
$321M
| $15.1M | 0.07% |
+1,128,557
| New | +$14.6M |
2026 Q2
0 quarters
|
|
57
Minerva Neurosciences
NERV
$114M
| $13.1M | 0.06% |
2,365,000
| – | – |
2025 Q4
2 quarters
|
|
58
Alamar Biosciences
ALMR
$2.18B
| $12.5M | 0.06% |
+462,900
| New | +$10.5M |
2026 Q2
0 quarters
|
|
59
Alvotech
ALVO
$1.83B
| $10.6M | 0.05% |
2,859,675
+2,660,000
| +1,332% | +$9.5M |
2024 Q3
7 quarters
|
|
60
Beta Bionics
BBNX
$993M
| $9.32M | 0.04% |
595,000
-3,012,920
| -84% | -$35.8M |
2025 Q1
5 quarters
|
|
61
InflaRx
IFRX
$228M
| $7.45M | 0.03% |
+3,325,000
| New | +$6.25M |
2026 Q2
0 quarters
|
|
62
ScottsMiracle-Gro
SMG
$3.26B
| $5.99M | 0.03% |
+88,000
| New | +$5.45M |
2026 Q2
0 quarters
|
|
63
Waystar Holding Corp
WAY
$5.53B
| $5.44M | 0.03% |
+264,900
| New | +$5.57M |
2026 Q2
0 quarters
|
|
64
Brunswick
BC
$4.24B
| $5.14M | 0.02% |
+61,000
| New | +$4.89M |
2026 Q2
0 quarters
|
|
65
Gentex
GNTX
$4.42B
| $5.03M | 0.02% |
+199,000
| New | +$4.71M |
2026 Q2
0 quarters
|
|
66
Idexx Laboratories
IDXX
$43.6B
| $4.74M | 0.02% |
+9,000
| New | +$5.05M |
2026 Q2
0 quarters
|
|
67
Prime Medicine
PRME
$691M
| $4.58M | 0.02% |
1,240,843
| – | – |
2024 Q1
9 quarters
|
|
68
Commercial Metals
CMC
$7.11B
| $4.2M | 0.02% |
+67,000
| New | +$4.71M |
2026 Q2
0 quarters
|
|
69
JATT II Acquisition Corp
JATT
$81.5M
| $3.41M | 0.02% |
+300,000
| New | +$3.19M |
2026 Q2
0 quarters
|
|
70
Sagimet Biosciences
SGMT
$708M
| $3.21M | 0.01% |
+415,000
| New | +$2.82M |
2026 Q2
0 quarters
|
|
71
Summit Midstream
SMC
$422M
| $1.66M | 0.01% |
58,214
| – | – |
2022 Q1
17 quarters
|
|
72
Teva Pharmaceutical Industries Limited
TEVA
$47.4B
| $1.36M | 0.01% |
40,000
-314,000
| -89% | -$10.5M |
2025 Q3
3 quarters
|
|
73
Revolution Medicines Inc Warrant
RVMDW
$114M
| $1.13M | 0.01% |
120,085
| – | – |
2023 Q4
10 quarters
|
|
74
Cogent Biosciences
COGT
$5.45B
| $658K | ﹤0.01% |
17,000
| – | – |
2020 Q4
22 quarters
|
|
75
AleAnna Inc Warrant
ANNAW
$8.52M
| $297K | ﹤0.01% |
990,000
| – | – |
2024 Q4
6 quarters
|
|
Similar funds
Thomas Steyer's Q2 2026 Portfolio in Review
As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Thomas Steyer withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.
- Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
- Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.